S. 2057 · 115th Congress
Pharmaceutical Regulation Conflict of Interest Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
BaldwinSponsor8 cosponsors · 8 D
6 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill amends the Ethics in Government Act of 1978 to prohibit a pharmaceutical regulator from using his or her position as regulator to influence any matter that provides a direct or substantial pecuniary benefit to a former employer or client.
What it does: CRS summary · Introduced in Senate · Nov 1, 2017
Pharmaceutical Regulation Conflict of Interest Act
This bill amends the Ethics in Government Act of 1978 to prohibit a pharmaceutical regulator from using his or her position as regulator to influence any matter that provides a direct or substantial pecuniary benefit to a former employer or client. The position of pharmaceutical regulator refers to any officer or employee occupying a supervisory position within the Drug Enforcement Administration or the Food and Drug Administration.
The bill also prohibits such a pharmaceutical regulator from participating in matters involving an individual or entity with whom the pharmaceutical regulator is negotiating future employment.
The bill expands restrictions on lobbying by such pharmaceutical regulators following separation from employment with a pharmaceutical regulatory agency.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Pharmaceutical Regulation Conflict of Interest Act
Latest action (Nov 1, 2017): Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Policy area: Government Operations and Politics · Origin: Senate · Introduced: Nov 1, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.